Krishna Vaddi
CEO at Prelude Therapeutics Incorporated
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Prelude Therapeutics Incorporated, 3 years.
Prelude Therapeutics Incorporated
Director · CEO
Chief executive roles
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 25, 2025 | Prelude Therapeutics Incorporated | Open-market purchase | +675,000 | $0.69 | $465,750 |
| Mar 21, 2025 | Prelude Therapeutics Incorporated | Open-market purchase | +15,000 | $0.73 | $10,950 |
| Mar 20, 2025 | Prelude Therapeutics Incorporated | Open-market purchase | +5,416 | $0.73 | $3,954 |
| Mar 17, 2025 | Prelude Therapeutics Incorporated | Open-market purchase | +9,106 | $0.75 | $6,830 |
| Mar 14, 2025 | Prelude Therapeutics Incorporated | Open-market purchase | +29,999 | $0.75 | $22,499 |
| Mar 13, 2025 | Prelude Therapeutics Incorporated | Open-market purchase | +50,000 | $0.72 | $36,000 |
| Mar 12, 2025 | Prelude Therapeutics Incorporated | Open-market purchase | +47,500 | $0.71 | $33,725 |
| Dec 31, 2024 | Prelude Therapeutics Incorporated | Open-market purchase | +5,000 | $1.21 | $6,050 |
| Dec 30, 2024 | Prelude Therapeutics Incorporated | Open-market purchase | +10,000 | $1.20 | $12,000 |
| Dec 19, 2024 | Prelude Therapeutics Incorporated | Open-market purchase | +6,888 | $0.89 | $6,130 |
| Dec 18, 2024 | Prelude Therapeutics Incorporated | Open-market purchase | +100,000 | $0.93 | $93,000 |
| May 25, 2023 | Prelude Therapeutics Incorporated | Open-market purchase | +900 | $5.31 | $4,779 |
| May 24, 2023 | Prelude Therapeutics Incorporated | Open-market purchase | +1,000 | $5.01 | $5,010 |
| May 23, 2023 | Prelude Therapeutics Incorporated | Open-market purchase | +11,856 | $5.63 | $66,749 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.